Clinical Trial Update: Mesenchymal Stem Cell for Acute Respiratory Distress Syndrome Due for COVID-19 [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for mesenchymal stem cells in acute respiratory distress syndrome associated with COVID-19 is in progress with an unknown status.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Distress Syndrome

Drugs mentioned

• Mesenchymal stem cells (mesenchymal stem cells)

Snippet

Sponsor: Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran | Conditions: Covid 19 | Phase 2 | Status: UNKNOWN